Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection-Reference-Cited by-同舟云学术

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

Published:2013-10 Issue:4 Volume:145 Page:790-800.e3
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Marcellin Patrick,Cooper Curtis,Balart Luis,Larrey Dominique,Box Terry,Yoshida Eric,Lawitz Eric,Buggisch Peter,Ferenci Peter,Weltman Martin,Labriola–Tompkins Emily,Le Pogam Sophie,Nájera Isabel,Thomas Denise,Hooper Gregory,Shulman Nancy S.,Zhang Ying,Navarro Mercidita T.,Lim Chin Yin,Brunda Michael,Terrault Norah A.,Yetzer Ellen S.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases;Ghany;Hepatology,2011

2. Telaprevir for previously untreated chronic hepatitis C virus infection;Jacobson;N Engl J Med,2011

3. Boceprevir for untreated chronic HCV genotype 1 infection;Poordad;N Engl J Med,2011

4. Response-guided telaprevir combination treatment for hepatitis C virus infection;Sherman;N Engl J Med,2011

5. Incivek [prescribing information],2012

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis;Nature Communications;2023-11-17

2. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials;Journal of Clinical and Experimental Hepatology;2019-07

3. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration;Applied Health Economics and Health Policy;2019-04-27

4. Danoprevir: First Global Approval;Drugs;2018-08

5. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo;Acta Pharmacologica Sinica;2018-06-21